The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

(NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today released the findings of their 2024 U.S. state and local End-of-Year Rates and Rules Report. It ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

In such a case, investors could be much better off buying sooner rather than later. What's so special about Jan. 30 for ...

The U.S. Bankruptcy Court for the Southern District of Texas allowed the company to exit bankruptcy as a privately-held company under the ownership of lenders. Those lenders include funds managed by ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...